RareCyte has appointed Frank Witney to its board of directors. Most recently, Witney served as president and CEO of Affymetrix, recently acquired by Thermo Fisher Scientific. He has previously served as president and CEO of Dionex and as president and CEO of Panomics, a subsidiary of Affymetrix. Prior to that, Witney served as president of PerkinElmer's Drug Discovery Tools division before it was acquired by Packard Bioscience in 2001. He served as president and chief operating officer at Packard Biosciences and he has also held leadership positions at Bio-Rad Laboratories.